BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 18042838)

  • 1. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study.
    Fizazi K; Oldenburg J; Dunant A; Chen I; Salvioni R; Hartmann JT; De Santis M; Daugaard G; Flechon A; de Giorgi U; Tjulandin S; Schmoll HJ; Bouzy J; Fossa SD; Fromont G
    Ann Oncol; 2008 Feb; 19(2):259-64. PubMed ID: 18042838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group.
    Fizazi K; Tjulandin S; Salvioni R; Germà-Lluch JR; Bouzy J; Ragan D; Bokemeyer C; Gerl A; Fléchon A; de Bono JS; Stenning S; Horwich A; Pont J; Albers P; De Giorgi U; Bower M; Bulanov A; Pizzocaro G; Aparicio J; Nichols CR; Théodore C; Hartmann JT; Schmoll HJ; Kaye SB; Culine S; Droz JP; Mahé C
    J Clin Oncol; 2001 May; 19(10):2647-57. PubMed ID: 11352956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer.
    Masterson TA; Shayegan B; Carver BS; Bajorin DF; Feldman DR; Motzer RJ; Bosl GJ; Sheinfeld J
    Urology; 2012 Jan; 79(1):156-9. PubMed ID: 22202548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
    Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
    BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors.
    Gumus M; Bilici A; Odabas H; Ustaalioglu BBO; Kandemir N; Demirci U; Cihan S; Bayoglu IV; Ozturk T; Turkmen E; Urakci Z; Seker MM; Gunaydin Y; Selcukbiricik F; Turan N; Sevinc A
    World J Urol; 2017 Jul; 35(7):1103-1110. PubMed ID: 27812752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients with non-seminoma germ cell tumours treated in a minor oncology department: the importance of multi-institutional protocols and research collaboration.
    Kildahl-Andersen A; Erke MG; Sagstuen H; Bremnes RM
    Acta Oncol; 2005; 44(6):537-44. PubMed ID: 16165912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late relapses (>2 years) in patients with stage I testicular germ cell tumors: predictive factors and survival.
    Fedyanin M; Tryakin A; Kanagavel D; Bulanov A; Burova A; Figurin K; Fainshtein I; Sergeev U; Zakharova T; Garin A; Tjulandin S
    Urol Oncol; 2013 May; 31(4):499-504. PubMed ID: 21803619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extragonadal and poor risk nonseminomatous germ cell tumors. Survival and prognostic features.
    Toner GC; Geller NL; Lin SY; Bosl GJ
    Cancer; 1991 Apr; 67(8):2049-57. PubMed ID: 1848473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium.
    Gillessen S; Sauvé N; Collette L; Daugaard G; de Wit R; Albany C; Tryakin A; Fizazi K; Stahl O; Gietema JA; De Giorgi U; Cafferty FH; Hansen AR; Tandstad T; Huddart RA; Necchi A; Sweeney CJ; Garcia-Del-Muro X; Heng DYC; Lorch A; Chovanec M; Winquist E; Grimison P; Feldman DR; Terbuch A; Hentrich M; Bokemeyer C; Negaard H; Fankhauser C; Shamash J; Vaughn DJ; Sternberg CN; Heidenreich A; Beyer J;
    J Clin Oncol; 2021 May; 39(14):1563-1574. PubMed ID: 33822655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved prognosis of patients with intermediate- and poor-risk nonseminomatous germ cell tumours by optimizing combined treatment.
    Pentheroudakis G; De Bono JS; Kaye SB; Simpson A; Paul J; Brown I; Pamenter B; Kirk A; Vasey P; Raby N; Kirk D
    BJU Int; 2003 Jul; 92(1):36-42. PubMed ID: 12823380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor.
    Dash A; Carver BS; Stasi J; Bajorin DF; Motzer RJ; Bosl GJ; Sheinfeld J
    Cancer; 2008 Feb; 112(4):800-5. PubMed ID: 18172902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contemporary management of postchemotherapy testis cancer.
    Daneshmand S; Albers P; Fosså SD; Heidenreich A; Kollmannsberger C; Krege S; Nichols C; Oldenburg J; Wood L
    Eur Urol; 2012 Nov; 62(5):867-76. PubMed ID: 22938868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary and Postchemotherapy Retroperitoneal Lymphadenectomy for Testicular Cancer.
    Heidenreich A; Paffenholz P; Nestler T; Pfister D
    Oncol Res Treat; 2018; 41(6):370-378. PubMed ID: 29772568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Factors and Treatment Results After Bleomycin, Etoposide, and Cisplatin in Germ Cell Cancer: A Population-based Study.
    Kier MG; Lauritsen J; Mortensen MS; Bandak M; Andersen KK; Hansen MK; Agerbaek M; Holm NV; Dalton SO; Johansen C; Daugaard G
    Eur Urol; 2017 Feb; 71(2):290-298. PubMed ID: 27649970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment and Outcome of Patients with Stage IS Testicular Cancer: A Retrospective Study from the Spanish Germ Cell Cancer Group.
    Aparicio J; Sánchez-Muñoz A; Ochenduszko S; Gumà J; Fernández-Aramburo A; García Del Muro X; Quiroga V; Sastre J; Alonso-Gordoa T; Sagastibelza N; Maroto P; Gómez de Liaño A; Vázquez S; Diz P; Durán I; Domenech M; Pinto A; Hernández A; González-Billalabeitia E; Terrasa J
    J Urol; 2019 Oct; 202(4):742-747. PubMed ID: 31163007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indolent nonseminomatous germ cell tumor of testis. Prolonged survival of patient with persistent metastatic disease.
    Baker TM; Chan AH; Stutz FH
    Urology; 1986 Apr; 27(4):349-52. PubMed ID: 3008399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the timing of orchiectomy on survival in patients with metastatic germ cell tumors of testis.
    Fedyanin M; Tryakin A; Bulanov A; Fainshtein I; Zakharova T; Matveev V; Garin A; Tjulandin S
    Urol Oncol; 2014 Jan; 32(1):32.e27-33. PubMed ID: 23628310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical evaluation of nonseminomatous testicular germ cell tumors].
    Nukui M; Nakao M; Nakagawa S; Takada H; Ebisui K; Sugimoto K; Watanabe H; Maekawa M
    Hinyokika Kiyo; 1991 Oct; 37(10):1281-5. PubMed ID: 1721771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgical Management of Cervical Non-seminomatous Germ Cell Tumor Metastases.
    Nwosu OI; Jones AJ; Alwani M; Einhorn LH; Moore MG; Mantravadi AV
    Laryngoscope; 2021 Jul; 131(7):1528-1534. PubMed ID: 33421136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of patients with clinical stage I nonseminomatous testicular germ cell tumours: active surveillance versus primary chemotherapy versus nerve sparing retroperitoneal lymphadenectomy.
    Heidenreich A; Pfister D
    Arch Esp Urol; 2012 Mar; 65(2):215-26. PubMed ID: 22414450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.